Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will present at the following investor conferences in November:
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following investor conferences in November:
- Stifel Virtual Healthcare Conference: fireside chat on Monday, November 16, 2020 at 8:40 am ET.
- Wolfe Research Virtual Healthcare Conference: fireside chat on Thursday, November 19, 2020 at 4:05 pm ET.
A live webcast of each presentation can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005213/en/
Investors
Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com
Media
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com
Source: Sage Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20201102005213/en